Is there a role for therapeutic drug monitoring with codeine?

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 249-256

  Kelly, Lauren E ^a   Madadi, Parvaz ^b  

^a WESTERN UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Codeine; Pharmacogenetics; Therapeutic drug monitoring

Indexed keywords

BUPRENORPHINE; CANNABINOID RECEPTOR; CATECHOL METHYLTRANSFERASE; COCODAMOL; CODEINE; CODEINE 6 GLUCURONIDE; CODEINE PHOSPHATE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DIAMORPHINE; DOPAMINE RECEPTOR; FENTANYL; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALORPHINE; NALOXONE; NORMORPHINE; OXYCODONE; PRODRUG; QUINIDINE SULFATE; SEROTONIN RECEPTOR; SPARTEINE;

ABCB1 GENE; ABDOMINAL PAIN; ALLELE; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CHRONIC PAIN; COMT GENE; CONFUSION; CONSTIPATION; COUGHING; CYP2D6 GENE; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TRANSFORMATION; EPIGASTRIC PAIN; EUPHORIA; FATIGUE; GENE; GENE DUPLICATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HETEROZYGOSITY; HUMAN; LOW DRUG DOSE; MORPHINE ADDICTION; MUSCLE CRAMP; NAUSEA; OPIATE ADDICTION; PAIN; PAIN THRESHOLD; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SOMNOLENCE; SWEATING; UGT2B7 GENE; VOMITING; WEAKNESS; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; CODEINE; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84862090949     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182557325     Document Type: Review

References (55)

1. Brunton L. On the use of codeine to relieve pain in abdominal disease. BMJ. 1888:1;1213-1214.
2. Eddy NB, Friebel H, Hahn KJ, et al. Codeine and its alternatives for pain and cough relief. Bull World Health Organ. 1968:38;673-741.
3. Wolff P. Codeine as a habit-forming drug. BMJ. 1938:12;997-998.
4. Slight D. Codeine addiction. CMAJ. 1935:32;69-71.
5. Mackenzie GK. Sensitivity to codeine. BMJ. 1949:30;266.
6. General Practitioner Research Group. Analgesic combinations of paracetamol and codeine. Practitioner. 1968:200;584-589.
7. Beecher HK, Keats AS, Mostellar R, et al. The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo "reactors" and "non-reactors". J Pharmacol Exp Ther. 1953:109; 393-400.
8. Dayer P, Desmeules J, Leemann T, et al. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monoxygenase catalysing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988:152; 411-416.
9. Sindrup S, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995:5;335-346. (Pubitemid 26011440)
10. Lotsch J, Rohrbacher M, Scmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain. 2009:144;119-124.
11. Sindrup S, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990:48;686-693.
12. Yue QY, Hasselstrom J, Svensson JO, et al. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991:31;635-642.
13. Desmeules, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol. 1991:41; 23-26.
14. Poulsen L, Brosen K, Arendt-Neilson L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol. 1996:51; 289-295. (Pubitemid 26422976)
15. Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995:274;516-520.
16. Persson K, Hammarlund-Udenaes M, Mortimer O, et al. The postoperative pharmacokinetics of codeine. Eur J Clin Pharmacol. 1992:42;663-666.
17. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993:90;11825-11829. (Pubitemid 24008732)
18. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007:7;257-265. (Pubitemid 47202488)
19. Dalen P, Frengel C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997:19;543-544. (Pubitemid 28116833)
20. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004:351; 2827-2831. (Pubitemid 40051906)
21. Koren G, Cairns J, Citayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006:368;704. (Pubitemid 44223697)
22. Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008:9; 1267-1284.
23. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metaboliser. Paediatr Anaesth. 2007:17;684-687. (Pubitemid 46911069)
24. von Muhlendahl KE, Scherf-Rahne B, Krienke EG, et al. Codeine intoxication in childhood. Lancet. 1976:2;303-305.
25. Ciszkowski C, Madadi P, Philips M, et al. Codeine, ultrarapid metabolism genotype and postoperative death. N Engl J Med. 2009:361; 827-828.
26. Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. Published online Apr 9, 2012 (doi: 10.1542/peds.2011-2538).
27. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012:91;321-326.
28. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008:83;234-242.
29. International association of therapeutic drug monitoring and clinical toxicology; Definition of TDM. Amended in 2011. Available at: http://www.iatdmct.org/index.php/publisher/articleview/frmArticleID/138. Accessed December 5, 2011.
30. Broadie MJ, Morag ME, Hallworth M. Therapeutic drug monitoring-the need for audit? Scott Med J. 1985:30;75-82. (Pubitemid 15056513)
31. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther. 2007:81; 899-902. (Pubitemid 46788300)
32. Richens A, Warrington S. When should plasma drug levels be monitored? Drugs. 1979:17;488-500. (Pubitemid 9173799)
33. Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth. 2002:89;839-845. (Pubitemid 35460521)
34. Stamer UM, Bayerer B, Stuber F. Genetics and variability in opioid response. Eur J Pain. 2005:9;101-104. (Pubitemid 40311825)
35. De Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol. 2007:27;241-245. (Pubitemid 46763304)
36. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 1997:7;375-379. (Pubitemid 27427547)
37. Sproule BA, Busto UE, Somer G, et al. Characteristics of dependent and nondependent regular users of codeine. J Clin Psychopharmacol. 1999: 19;367-372. (Pubitemid 29344852)
38. Groudine SB, Cresanti-Dankins C, Lumb PD. Successful treatment of massive intrathecal morphine overdose. Anesthesiology. 1995:82;292-295.
39. Albertson TE. Opiates and opioids. In: Olson KR, ed. Poisoning & Drug Overdose. 5th ed. New York, NY: McGraw-Hill; 2007. Available at: http://www.accessmedicine.com/content.aspx?aID=2678355. Accessed February 13, 2012.
40. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Distrib. 1996;25;1-4.
41. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breasted neonate of a mother prescribed codeine. Can Fam Physician. 2007:53;33-35. (Pubitemid 46166581)
42. Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003:73;566-574. (Pubitemid 37249128)
43. Darbari DS, van Schik RH, Capparelli EV, et al. UGT2B7 promoter variant-840G.A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. 2008:83; 200-202. (Pubitemid 351303943)
44. Campa D, Gioia A, Tomei A, et al. Association of ABCB1éMDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008:83;559-566. (Pubitemid 351417058)
45. Klepsted P, Rakbag TT, Kaasa S, et al. The 118A.G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004:48;1232-1239. (Pubitemid 39490855)
46. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003:299;1240-1243. (Pubitemid 36237467)
47. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005: 116;73-78. (Pubitemid 40828502)
48. Saady JJ, Narasimhachari N, Blanke RV. Rapid, simultaneous quantification of morphine, codeine, and hyfromorphone by GC/MS. J Anal Toxicol. 1982:6;235-237. (Pubitemid 12036250)
49. Meadway C, George S, Braithwaite R. A rapid GC-MS method for the determination of dihydrocodeine, codeine, norcodeine, morphine, normorphine and 6-MAM in urine. Forensic Sci Int. 2002:127;136-141. (Pubitemid 34722772)
50. Barnes AJ, Kim I, Schepers R, et al. Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with Cozard Opiate Microplate EIA and GC-MS following controlled codeine administration. J Anal Toxicol. 2003:27;402-406. (Pubitemid 37185848)
51. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997:60;284-295. (Pubitemid 27058401)
52. Walson PD. Therapeutic drug monitoring in special populations. Clin Chem. 1998:44;415-419. (Pubitemid 28087749)
53. Pippenger CE. Therapeutic drug monitoring: an overview. Ther Drug Monit. 1979:1;3-9. (Pubitemid 10042712)
54. Ensom MH, Chang TK, Patel P. Pharmacogenetics the therapeutic drug monitoring of the future? Clin pharmacokinet. 2001:40; 783-802. (Pubitemid 33095996)
55. Wu AH. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics. 2011: 8;12-20.